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Background: Escherichia coli isolates producing extended-spectrum −lactamases 35 
(‘ESBL-E. coli’) cause >5000 bacteraemias annually in the UK. The contribution of 36 
the food chain to this challenge is debated.  Methods: Selective media were used to 37 
seek ESBL-E. coli in routinely-submitted human faeces, sewage, farm slurry, and 38 
retail foodstuffs in London, East Anglia, Northwest England, Scotland and Wales. 39 
Recovered isolates were sequenced and compared with 293 bloodstream and 83 40 
veterinary surveillance ESBL-E. coli isolates from the same regions. Findings: 41 
10.7% (2157/20243) of human faeces contained ESBL-E. coli, rising to 17.0% 42 
(678/3995) in London. ESBL-E. coli also were frequent in sewage and present in 43 
65.4% (104/159) of retail chicken, but rare in other meats and absent from plant-44 
based foods. Sequence Type (ST) 131 dominated among ESBL-E. coli from human 45 
blood (188/293, 64.2%), faeces (128/360, 35.6%) and sewage (14/65, 21.5%) with 46 
STs 38 and 648 also widespread; CTX-M-15 was the predominant ESBL in these 47 
lineages.  By contrast, STs 602, 23, 117 - mostly with CTX-M-1 ESBL - dominated 48 
among food and veterinary isolates, with only two ST131 organisms recovered. 49 
ST10 occurred in both animals and humans: being frequent in surveillance bovines 50 
and representing 4.2% (15/360) of human faecal isolates (but only 1% [3/293] from 51 
bacteraemias); however both human and animal ST10 isolates were diverse in 52 
serotype. Interpretation: Most human bacteraemias with ESBL-E. coli in the UK 53 
involve successful human-associated STs, particularly ST131; non-human reservoirs 54 
made little contribution to invasive human disease. Funding: NIHR Policy Research. 55 
56 
Introduction  57 
Escherichia coli is a Jekyll and Hyde organism: a few lineages are virulent 58 
enteropathogens whereas most are innocuous gut commensals, harmful only if they 59 
reach other body sites - notably the urinary tract, where E. coli is the commonest 60 
pathogen.  Most E. coli urinary tract infections (UTIs) are uncomplicated cystitis, but 61 
some ascend, affecting the kidneys and, at worst, causing overspill bacteraemia. 62 
Although such sequelae are rare, E. coli is now the commonest bloodstream 63 
pathogen in England, with 41060 cases in fiscal 2017/18 - 27.1% more than in 64 
2012/13.[1] Most E. coli bacteraemias have a urinary origin [2] and, in the UK c. 60% 65 
are caused by ‘Extraintestinal Pathogenic E. coli’ (ExPEC) lineages belonging to 66 
sequence types (STs) 12, 69, 73, 95 and 131.[3] 67 
Cephalosporin resistance mediated by extended-spectrum −lactamases 68 
(ESBLs] has proliferated in E. coli since 2000 [4], now occurring in c. 10-12% of UK 69 
bloodstream isolates.  This proportion suggests around 4900 ‘ESBL-E. coli’ 70 
bacteraemias annually in England (41060 x 12%), and more across the whole UK. 71 
[1], often due to multiresistant ST131 isolates.[3,5], ESBL production and 72 
multiresistance increases the risk that empirical treatment will fail, doubling the 17-73 
18% mortality rate typical for E. coli bacteraemia.[6-8]  74 
ESBL-E. coli also are widespread in sewage, pets, meat and food animals, 75 
but the extent of transmission between these milieux and humans is uncertain, with 76 
the role of the food chain debated. [9-11]  A meta-analysis identified 6 ‘adequate’ 77 
studies suggesting food-to-human transmission of ESBL-E. coli against 17 finding 78 
foodborne transmission was unimportant. [9]  We sought to clarify the contribution of 79 
foodborne ESBL-E coli to human colonisation and infection, using whole genome 80 
sequencing (WGS) to compare isolates from multiple sources across the UK.  81 
82 
Materials and methods 83 
Isolates 84 
Consecutive bloodstream ESBL-E. coli were obtained during 2013 and 2014 from 85 
NHS laboratories in 5 UK Regions, with 5 sites in East Anglia, 2 each in Northwest 86 
England, Scotland and Wales and 1 in London. Identification and susceptibility 87 
testing were by laboratories’ local protocols, with presumptive ESBL-E. coli sent to 88 
Public Health England (PHE) Colindale to a quota of 80/Region, along with brief, 89 
anonymised, patient details. 90 
Isolates from other sources were collected prospectively in the 5 Regions, as 91 
detailed below. Isolation involved plating samples onto CHROMagar ESBL and 92 
CHROMagar CTX (CHROMagar, Paris France), prepared according to the 93 
manufacturer’s directions, and hereafter referred to as ‘The two chromogenic media’. 94 
For human faecal sampling, which was decentralised, these media were prepared at 95 
PHE Colindale and distributed weekly to laboratories; other testing was centralised 96 
at PHE Colindale and the Animal and Plant Health Agency. 97 
 98 
ESBL-E. coli in human faeces 99 
Faecal specimens were as submitted from May 2013 to June 2014 for detection of 100 
intestinal pathogens or occult blood screening at Barts Health (London), the Norfolk 101 
& Norwich University Hospital (East Anglia), Lancashire Hospitals Trust, Central 102 
Manchester University Hospitals (Northwest England), Aneurin Bevan University 103 
Health Board (Wales) and NHS Greater Glasgow and Clyde (Scotland). Each 104 
laboratory was asked to randomly select and test 15-20 faecal specimens/day to a 105 
maximum of 100/week.  106 
 Faeces (c. 0.5 g) was mixed with 1 ml 0.85% saline, then 50-µl aliquots were 107 
spread on the two chromogenic agars and incubated for 18-24h. Presumptive ESBL-108 
E. coli (pink on CHROMagar ESBL or blue on CHROMagar CTX) were retained.  109 
 110 
ESBL-E. coli in sewage  111 
Paired inflow and effluent samples (50-1000 ml) were obtained from multiple sewage works 112 
belonging to 4 water companies covering Scotland, Northwest England, London and Wales 113 
(East Anglia did not participate). Each region provided 4 batches of samples between 114 
November 2013 and December 2014, with c. 80 samples/region. These were couriered to 115 
PHE Colindale at 2-8oC, stored at 2-10oC and processed within 24h. Volumes (0.01-10 ml) 116 
were filtered through 0.45-µm pore membranes, which were washed with distilled water 117 
before transfer to absorbent pads saturated with lauroyl sulphate broth for 4h at 30oC, then 118 
to lauroyl sulphate agar for 14h before enumeration of yellow colonies as presumptive E. 119 
coli. Lastly, one filter per sample was transferred to each CHROMagar and incubated at 120 
37oC for 18-24h. Colonies that continued to develop, becoming appropriately coloured for 121 
ESBL-E. coli, were retained at 4oC. A simplified method was also followed whereby bacteria 122 
were pelleted from c. 30 ml sewage, resuspended in 0.5 ml of ‘Freezing Broth’ and retained 123 
at -70 C. Putative ESBL-E. coli were recovered, as red colonies, after plating 100 l of 124 
defrosted material on UTI Brilliance Agar (Oxoid, Basingstoke, UK) containing 10-mg/L 125 
cefotaxime. 126 
 127 
ESBL-E. coli in food 128 
These methods and corresponding results have been published previously. [12]   129 
Beef, pork and chicken (n=397 in a 2:1:2 ratio, reflecting market share), also grapes 130 
(n=50 samples), strawberries (n=38), raspberries (n=35), blueberries (n=27), celery 131 
(n=50), carrots (n=50), onions or spring onions (n=50), lettuce (n=50), coriander 132 
(n=43) and basil (n=7) were bought in each of the 5 Regions.[12] Retailers included 133 
leading supermarkets, discount stores, convenience stores and local 134 
butchers/greengrocers, in proportion to market share. Beef and chicken were 135 
obtained on 5 occasions between August 2013 and February 2014, pork on 4 136 
occasions from October 2013 to February 2014 and vegetables on 15 occasions 137 
from January to March 2014.  Meat samples were processed by APHA; fruit, 138 
vegetables and herbs by PHE, with the two chromogenic agars used to recover 139 
presumptive ESBL-E. coli. 140 
 141 
ESBL-E. coli in slurry 142 
Slurry samples (n=97) were collected from representative dairy farms across the 5 143 
Regions in January/February 2014, after milking and before cleaning, sampling 5 144 
floor areas/farm, with ‘London’ represented by the Home Counties. 1-g samples 145 
were incubated overnight at 37°C in 9 ml of Buffered Peptone Water before plating 146 
10-l amounts on the 2 chromogenic media. 147 
 148 
ESBL-E. coli from veterinary diagnostic surveillance  149 
These were veterinary diagnostic submissions to APHA or its predecessor 150 
laboratories from prospective surveillance across the 5 Regions and from scanning 151 
surveillance of food animals. The latter entails laboratory investigations of animal 152 
disease, largely post-mortem or through sample submission. Investigation seeks the 153 
cause of disease, and E. coli may be recovered and characterised. The isolates 154 
comprised all ESBL-E. coli submitted across the 5 Regions during 2011-13, 155 
irrespective of their contribution to disease. 156 
 157 
Characterisation of presumptive ESBL-E. coli  158 
Presumptive ESBL-E. coli, isolated as above from blood, faeces, sewage, food, 159 
animals and slurry were received at PHE and screened for blaCTX-M, blaTEM, blaSHV 160 
and blaOXA by multiplex PCR.[13] blaCTX-M-positive isolates were accepted as ESBL-161 
producers, whilst those positive for one of the other -lactamase genes were 162 
subjected to double disc ESBL tests using amoxicillin-clavulanate (20+10 μg) discs 163 
c. 20 mm apart (centre-to-centre) from cefotaxime (30 μg), ceftazidime (30 μg) and 164 
cefepime (30 μg) discs. Expansion of an oxyimino-cephalosporin zone towards the 165 
amoxicillin-clavulanate disc implied ESBL production.[14] Isolates positive by these 166 
methods were confirmed as E. coli by MALDI-ToF (Bruker Maldi-Biotyper, Bremen, 167 
Germany); any flagged as Shigella were confirmed as E. coli based on o-nitrophenyl-168 
β-D-galactosidase activity and a 603-bp PCR product for ipaH. [15] Definitive 169 
confirmation as ESBL-E. coli was by WGS (HiSeq 2500, Illumina, San Diego, CA, 170 
USA). STs were assigned and −lactamase genes sought using the in-house 171 
‘Genefinder’ pipeline. [16] ST131 isolates were assigned to clades based on fimH 172 
sequences [17] serotypes of ST10 isolates (which crossed among host species) 173 
were deduced from sequence data. [18]  174 
 175 
Statistical methods 176 
Analysis was primarily descriptive, with presentation of proportions as percentages and of 177 
continuous variables as mean and standard deviation. Pearson’s chi-squared test was used 178 
to compare proportions, with R version 3.5.0. 179 
 180 
Role of funder 181 
This paper reports independent research commissioned and funded by the NIHR 182 
Policy Research Programme (Defining Reservoirs of ESBL-Producing E. coli and the 183 
Threat Posed to Personal, Animal and Public Health in the UK). The views 184 
expressed are those of the author(s) and not necessarily those of the NHS, NIHR, 185 
Department of Health and Social Care, ‘Arms-Length Bodies’ or other government 186 
departments. The sponsor had no role in study design, data collection, analysis or 187 
interpretation, nor in writing this report. The corresponding author had full access to 188 
all study data and had final responsibility for the decision to submit for publication.  189 
 190 
Results 191 
Bloodstream isolates: reference group 192 
ESBL production was confirmed in 293/327 (89.6%) bloodstream isolates received 193 
as ESBL-E. coli (Table 1). Case Record Forms were available for 244/293 (83.2%), 194 
with a lower availability for London isolates (32.7%; Pearson’s chi-squared test p < 195 
0.001). There was a small excess of men; the mean age was 70 years, though 196 
younger in London (58.9 years; Kruskal-Wallis rank sum test p = 0.002); 61.4% of 197 
the 285 cases with data were community presentations, or hospitalised <48h.  Data 198 
on the origin of bacteraemia were available for c. 50% of patients, with genitourinary 199 
(60.0%) and gastrointestinal/hepatobiliary sources (18.3%) predominating; few 200 
patients were identified as post-surgical (9.1% of 209 with data), but post-discharge 201 
re-presentations may be under-recorded. 202 
 203 
Faecal ESBL-E. coli 204 
20,243 faecal samples were screened, comprising 3995-4112 per region (Table 2). 205 
2107 (10.4%) gave colonies of the appropriate colour for E. coli on CHROMagar 206 
ESBL, 1302 (6.4%) on CHROMagar CTX, and 1252 (6.2%) on both. If 207 
appropriately-coloured growth on either medium – as seen for 2157 (10.7%) 208 
specimens – was taken as positive, regional ESBL prevalence ranged from 8.5-209 
9.8%, except for London, 17.0% (p <0.001) (Table 2).  400 of the presumptive ESBL-210 
E. coli (80/region) were forwarded to PHE, and WGS found ESBL genes in 360 of 211 
these (90%). The 40 isolates lacking ESBL genes split between cephalosporin-212 
susceptible E. coli (n=20), E. coli with other resistance mechanisms (n=18) and non-213 
E. coli (n=2).  Accordingly ESBL prevalence may be up to 10% lower than suggested 214 
in Table 2; though some detection failures likely reflect plasmid loss, reducing this 215 
correction factor.  216 
 Data were available for 355/360 carriers (Table 2). Their age distribution was 217 
bimodal, peaking at <5 and 75-79 years. Males comprised 50-63.6%, according to 218 
Region, and in-patients 29.9% (London) to 65.2% (Scotland). Overseas travel was 219 
reported for 99 patients (27%), with South and Southeast Asia the leading 220 
destinations (n=33); recent travellers accounted for 41.6% and 57.5% of the London 221 
and Wales patients but <20% elsewhere. Significant gastrointestinal pathogens were 222 
identified by local laboratories in only 11% of patients whilst recent exposure to 223 
antimicrobials was established for 32 (9%); 11 had received piperacillin/tazobactam. 224 
 225 
ESBL-E. coli from sewage 226 
163 inflow and 162 effluent samples were submitted. Failure of the selective media 227 
adequately to suppress developing colonies of ESBL-negative E. coli on the transfer 228 
membranes precluded accurate calculation of ESBL prevalence; nevertheless, a 229 
panel of 65 sewage ESBL-E. coli was assembled, 41 from Wales, 18 from London 230 
and three each from Scotland and Northwest England.  231 
 232 
ESBL-E. coli from food, bovine slurry and animals 233 
Results of screening foodstuffs have been published separately.[12] ESBL-E. coli 234 
were recovered from 65.4% (104/159) of chicken samples, with positivity rates from 235 
40.6% (13/32 Scotland) to 80.6% (25/31 Northwest England (p <0.0001). 236 
Contamination may arise from the original bird or be acquired during slaughter and 237 
processing. Even with enrichment, only 1.9% (3/159) of beef and 2.5% (2/79) of pork 238 
samples yielded ESBL-E. coli, based on growth on either chromogenic medium. No 239 
ESBL-E. coli were recovered from 400 fruit and vegetable samples, many of 240 
international origin.  241 
 19 to 20 dairy-farm slurry samples were tested per region, with an ESBL-E. 242 
coli positivity rate, based on growth on either medium, of 27.8% (27/97).  Regional 243 
rates were from 15% (Scotland, 3/20) to 40.0% (Northwest England, 8/20).   244 
 These prospective collections were supplemented with 83 ESBL-E. coli from 245 
the APHA’s scanning surveillance of food animals. These were from the same 246 
Regions as the other series, with ‘London’ again including the Home Counties; 51 247 
isolates were from cattle, 29 from chickens with singletons from other species.  248 
  249 
ESBL-E. coli STs in relation to specimen source 250 
Table 3 lists the top 10 ESBL-E. coli STs for each specimen type, so long as these 251 
had >3 representatives. ST131 greatly predominated in human bacteraemias, 252 
comprising 188/293 (64.2%) isolates. It was also the most prevalent ST, though less 253 
overwhelmingly so, in faeces (128/360 isolates, 35.6%) and sewage 14/65 (21.5%). 254 
Regional proportions of ST131 among bloodstream isolates were: London 36/55 255 
(64.5%); East Anglia 40/66 (60.6%); Northwest England 29/61 (47.5%); Scotland 256 
28/37 (75.5%) and Wales 55/74 (74.3%); corresponding proportions among faecal 257 
isolates were London 16/77 (20.8%), East Anglia 16/67 (23.9%), Northwest England 258 
27/75 (36.0%), Scotland 37/68 (54.4%) and Wales 32/72 (44.4%). Regional variation 259 
in the ST131 proportion was significant for both blood (p 0.01) and faeces (p 260 
<0.0001). 261 
Other frequent bloodstream STs, in descending rank order, were 38, 648, 262 
405, 73, 69, 636, 95, 1193 and 10. Several of these were also prominent in other 263 
human-related sources: thus, STs 38, 405, 636 and 648 were among the top 10 264 
types among faecal isolates, with ST38 in second rank and ST648 fourth; ST38 was 265 
the second ranked ST from sewage, followed by ST10. By contrast, the top-ranked 266 
STs from meat and animals were 602, 23, 117 (or its single locus variant, ST6284) 267 
and ST10. There was species specificity within the animal isolates, with STs 23 and 268 
602 dominating for chickens and chicken meat, whereas STs 10, 117 and 6284 269 
dominated in cattle and their slurry (Table 3).  270 
The top-ranked human types were rare in meat, animals and slurry. Just two 271 
ST131 isolates were recovered from animal-related sources: one from chicken meat 272 
and another from a surveillance chicken; both belonged to ST131 clade B whereas 273 
over 95% of bloodstream, faecal and sewage ST131 isolates belonged to clades C1 274 
and (mostly) C2. STs 38, 648, 405, 73, 636, 95 and 1193 were not seen in animal-275 
associated sources, and ST69 was seen in just one isolate from chicken meat and 276 
one from a cow. Only ST10, which accounted for 15/360 (4.2%) human faecal 277 
isolates and 3/293 (1.0%) from blood was widely seen in bovines and their slurry, 278 
though not in meat (Table 3). This human/animal overlap for ST10 was more 279 
apparent than real, however: the total of 38 ST10 isolates were deduced to belong to 280 
26 different combinations of O (somatic) and H (flagellar) serotype, with the 3 human 281 
bloodstream isolates and 12/15 (87%) of human faecal isolates belonging to 282 
serotypes not seen from animal sources. 283 
The predominant animal-related STs were infrequent in humans.  ST602 - the 284 
top ST from meat (specifically  chicken) - was not seen from human bacteraemias 285 
and had only 2 representatives from human faeces.  Among all 293 human 286 
bacteraemia isolates just 5 (1.6%) belonged to top-ranked types from any animal-287 
related source, specifically the 3 ST10 isolates and single representatives of STs 23 288 
and 117.  289 
 290 
 291 
ESBLs in relation to ST 292 
CTX-M-15 enzyme predominated in human bloodstream, faecal, and sewage 293 
isolates (Table 4). This substantially reflected its association with ST131, but it 294 
remained the most prevalent ESBL in other major STs from these sources except 295 
ST38, where CTX-M-14 narrowly predominated. A sizeable minority (14.2%, 24/188) 296 
of ST131 isolates had CTX-M-27, not CTX-M-15.  297 
By contrast, CTX-M-1 was considerably the most frequent ESBL among meat 298 
(chicken) isolates, whereas CTX-M-15 was not seen and most other ESBLs were 299 
SHV or TEM types.  CTX-M-1 also predominated (20/29 cases) in surveillance 300 
chickens whilst CTX-M-14 dominated in cattle, with 30 examples versus 12 CTX-M-301 
15, 3 CTX-M-27 and 7 isolates with other CTX-M types. Major hosts of CTX-M-1 302 
enzyme in chickens and their meat were STs 23 and 602, whereas ST10 and 303 
ST117/ST6284 were the frequent hosts of CTX-M-14 among bovines. Despite its 304 
frequency in E. coli from chickens and their meat, CTX-M-1 enzyme was seen in 305 
only 10/293 human bloodstream isolates, 21/360 from faeces and 7/65 from sewage. 306 
It mostly occurred in minor human STs, with only one or 2 representatives apiece. 307 
The solitary exception (again) was ST10, where CTX-M-1 was present in 3/15 308 
human faecal isolates. The ST23/CTX-M-1 and ST602/CTX-M-1 combinations, 309 
widespread in chickens and their meat, were only seen in single human faecal 310 
isolates and never in blood.  CTX-M-14 - the most frequent ESBL from the bovine 311 
isolates - was widely seen in major human blood and faecal isolates, including 312 
ST131 and ST38, but the ST10/CTX-M-14 combination, frequent in cattle, had only 313 
single representatives from human faeces and blood, whilst ST117/ST6284 CTX-M-314 
14 was not seen.  There was a single bloodstream ST117 isolate with CTX-M-1 315 
enzyme, matching a combination seen in 10 isolates from chickens or their meat.  316 
 317 
Discussion 318 
We compared ESBL-E. coli from human bacteraemias with those from human 319 
faeces, sewage, food, slurry and animals across 5 UK regions. Bloodstream isolates 320 
followed expected patterns: largely from older patients with community-associated 321 
infection of genitourinary or gastrointestinal origin.[2] Faecal ESBL-E. coli were often 322 
linked to foreign travel, particularly to South or Southeast Asia or prior antibiotics, in 323 
keeping with the literature.[19,20] Greater contamination of chicken than other meats 324 
also concurs with previous findings (see also [12]). 325 
 Typing and ESBL results (Tables 3 and 4; summarised in figure 1), indicated 326 
commonality between human bloodstream ESBL-E. coli and those from faeces and 327 
sewage, with STs 131 (especially), 38 and 648, prominent in all, largely with CTX-M-328 
15 enzyme. Likewise, there was commonality between the lineages from 329 
surveillance chickens and chicken meat, with STs 23 and 602 dominating, often with 330 
CTX-M-1 ESBL, and between cattle and their slurry, where ST10 (with CTX-M-14 or 331 
-15) dominated. On the other hand, there was little crossover between types from 332 
humans, chickens, and bovines, with only (serotype diverse) ST10 among the top-333 
10-ranked types from humans, animals and meat; ST117 was widely seen from both 334 
bovines and chickens. Other foodstuffs besides chicken showed little contamination.  335 
 Our findings do not support the assertion that the ESBL-E. coli causing 336 
invasive human infections are disseminating via the food chain. Rather, they support 337 
the view that host-adapted ESBL-E. coli lineages are circulating, with limited inter-338 
species transmission.  This conclusion agrees with the majority of studies included in 339 
recent meta-analysis.[9] ST131, which dominated among human-related isolates, is 340 
well-known and often multiresistant.[5,21] Although it occasionally occurs in food 341 
animals, (as in 2 instances here) the animal ST131 clades are generally different,[22] 342 
as here.  At the upper edge of the reported prevalence range, Johnson et al.[23] in 343 
the US found 5/25 ESBL-E. coli from chickens or chicken meat belonged to ST131. 344 
By contrast, we - and a previous investigation covering the UK, Germany and the 345 
Netherlands [24] found only occasional ST131 isolates from food and animals. This 346 
rarity is supported by a major review,[5] cataloguing many individual detections of 347 
ST131 from food or food animals, but no dissemination.  348 
 Other common types from bacteraemia – ST38 and ST648 (each accounting 349 
for c. 5% of cases versus 64.2% for ST131) – were absent from food or animals. The 350 
literature carries reports of ST38 (with CMY-2, rather than ESBLs) from poultry, 351 
humans and wildlife [25]; ST648 too is largely reported from humans, though 352 
carriage was seen in horses and dogs.[26] Among the major meat and animal types, 353 
ST23 was reported from an outbreak in a French hospital,[27] with various further 354 
one-off reports but, as here, is largely a poultry type,[28] as is ST117,[21] which has 355 
spread in Nordic broiler production.[29] ST602, although frequent here, is less 356 
reported previously.  ST10, as the sole lineage to appear in the ‘top 10’ of both 357 
human bloodstream and food-animal or meat-associated groups has been 358 
repeatedly noted by others in both animals and humans; nonetheless the serotype 359 
diversity seen here argues against simple direct flows of ST10 along the food-chain.  360 
The present results are in keeping with those of a comparison of ESBL-E. coli from 361 
human bacteraemias and livestock in the East of England – one of the regions also 362 
surveyed here – which also found that these isolate groups and their resistance 363 
determinants are largely distinct.[30] 364 
 Rather than the food chain, the likeliest frequent route of transmission for 365 
human-adapted ESBL-E. coli is human to human oro-faecal. This would account not 366 
only for the strain and enzyme distributions summarised in Figure 1 but also the 367 
regional variation in gut carriage of ESBL-E. coli (Table 2) with higher rates in 368 
London, where sampling was solely from the Royal London Hospital, which 369 
predominantly serves poor, crowded areas and populations with frequent travel to 370 
and from south Asia. A study in the UK West Midlands similarly observed that human 371 
gut carriage of ESBL-E. coli was more prevalent in inner city conurbations (i.e. 372 
around Birmingham) than in rural Shropshire.[31]  We cannot exclude that some 373 
small minority of human infections may have a direct origin from food, nor that local 374 
clusters may occur. Canadian authors [32,33] stress local finding of near-identical 375 
ST131 and ST117 E. coli (ESBL-producing or not) from both retail chicken meat and 376 
human infections; nevertheless these putative ‘crossovers’ accounted for only a tiny 377 
minority of all the human and animal E. coli they collected.  Further, we cannot 378 
exclude the possibility that some future multi-resistant E. coli lineage from one or 379 
more food animal species will also prove adept at colonising and infecting humans.  380 
And, one further caveat remains: we do not know when, where, or how often blaCTX-M 381 
genes escaped from Kluyvera spp. (where they are endogenous and chromosomal) 382 
to mobile DNA, nor the chain of transmission to human-adapted E. coli lineages. 383 
However, it seems logical that the hazard of such gene escape will multiply with the 384 
range of animal species - and intestinal microbiotas - exposed to selective 385 
antibiotics.[34] 386 
 The present findings suggest that efforts to stop the rise of ESBL-E. coli in 387 
invasive infections should concentrate upon (i) disrupting oro-faecal transmission by 388 
good post-toilet hygiene, e.g. in care homes; (ii) on prevention of UTIs by good 389 
hydration and catheter care, and on (iii) prompt effective treatment of preceding 390 
UTIs. Vaccines may provide a future answer, with promising early results for cystitis 391 
in younger women.[35]  Efforts to counter the spread of ESBL-E. coli in food 392 
production seem unlikely to impact greatly on the tally of invasive human infections 393 
but remain important in ensuring that veterinary infections remain tractable. 394 
 395 
Panel 396 
Research in context. E. coli producing acquired extended-spectrum −lactamases 397 
(‘ESBL-E. coli’) are the largest group of multi-resistant pathogens from bacteraemias 398 
in the UK, presenting major challenges. E. coli is also the major aerobic component 399 
of the human and animal gut biota and a frequent contaminant of meat and the 400 
environment. Extensive literature reviews in 2011-2 were summarised in a joint 2012 401 
report of ESBL-E. coli by UK Government Advisory Committees. [11] This, and 402 
subsequent publications, recorded considerable uncertainly on the contribution of 403 
food-borne and environmental ESBL-E. coli to human colonisation and invasive 404 
infection. Thus, for example, early Dutch studies suggested some match between 405 
ESBL-E. coli from humans and poultry farming whereas a larger subsequent study 406 
covering the UK, Netherlands and Germany did not support such a linkage. [24]   A 407 
meta-analysis[9] identified 6 ‘adequate’ studies suggesting food-to-human 408 
transmission of ESBL-E. coli versus 17 that argued against this view.  These 409 
uncertainties led initiation of a competitive NIHR Policy Research Programme and, 410 
among various activities, this programme funded the present comparison of ESBL-E. 411 
coli from human and animal sources. Reviews of the recent literature, to support the 412 
present paper, were undertaken by searching PubMed with combinations of the 413 
terms Escherichia coli, ESBL, CTX-M, meat, poultry, bacteraemia, faeces and UTI. 414 
Added value of this study. We showed, comprehensively, that the ESBL-E. coli 415 
strains from bacteraemias in the UK match those prevalent as human gut colonists 416 
and in sewage. However they are largely distinct – in respect of strain and ESBL 417 
types – from those in food animals and retail food.  418 
Implications of all available evidence. In 2016 the UK Government indicated its 419 
aim to achieve a 50% reduction in serious Gram-negative infections by 2020. A 420 
reduction in the numbers of infections due to ESBL-E. coli is especially desirable, 421 
given their incidence (>5000 cases p.a.) and the treatment challenges. The present 422 
data shows that actions on the food chain, however desirable for animal husbandry, 423 
are unlikely to contribute to reducing human infection. Better potential control points 424 
are (i) prevention of transmission by good post-toilet hygiene e.g. in care homes and 425 
(ii) prevention of severe infection by good patient care and rapid effective treatment 426 
of initial uncomplicated UTIs, which precipitate most of the bacteraemias. Vaccines 427 
may be a future answer. 428 
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 Table 1. Sources of ESBL-E. coli isolates from bloodstream infections 601 
 E Anglia London Northwest Scotland Wales All 
Total no. cases  66 55 61 37 74 293 
No with data 55 18 61 37 72 243 
Basic demographics       













Male % 45.5 61.1 44.3 56.8 55.6 51.2 
Source of isolate (%)       
Community/Outpatient a 2 (8.0) 10 (55.6) 6 (10.9) 0 (0.0) 2 (4.2)   20 (10.9)  
Inpatient (> 48h) 5 (20.0) 4 (22.2) 21 (38.2) 12 (32.4) 29 (60.4)   71 (38.8)  
Inpatient (< 48h) 18 (72.0) 4 (22.2) 28 (50.9) 25 (67.6) 17 (35.4)   93 (50.3)  
Specialty (%)       
A & E 13 (23.6) 6 (33.3) 12 (22.6) 20 (54.1) 16 (22.2)   67 (32.1)  
Intensive care 0 (0.0) 3 (16.7) 3 (5.7) 2 (5.4) 2 (2.8)   10 (4.8)  
Medical 29 (52.7) 8 (44.4) 24 (45.3) 9 (24.3) 25 (34.7)   95 (45.5)  
Paediatrics 2 (3.6) 0 (0.0) 3 (5.7) 0 (0.0) 0 (0.0)   5 (2.4)  
Surgical 11 (20.0) 0 (0.0) 4 (7.5) 2 (5.4) 2 (2.8)   19 (9.1)  
Other 0 (0.0) 1 (5.6) 7 (13.2) 4 (10.8) 1 (1.4)   13 (6.2)  
Origin (%)       
Gastrointestinal/biliary 7 (17.5) 5 (33.3) 3 (11.1) 6 (19.4) 1 (14.3)   22 (18.3)  
Genitourinary tract 27 (67.5) 6 (40.0) 14 (51.9) 23 (74.2) 2 (28.6)   72 (60.0)  
Line related  0 (0.0) 1 (6.7) 2 (7.4) 1 (3.2) 2 (28.6)   6 (5.0)  
Respiratory 4 (10.0) 1 (6.7) 1 (3.7) 1 (3.2) 2 (28.6)   9 (7.5)  
Skin/soft tissue 0 (0.0) 0 (0.0) 2 (7.4) 0 (0.0) 0 (0.0)   2 (1.7)  
Surgical site infection 0 (0.0) 2 (13.3) 0 (0.0) 0 (0.0) 0 (0.0)   2 (1.7)  
Other  2 (5.0) 0 (0.0) 5 (18.5) 0 (0.0) 0 (0.0)   7 (5.8)  
 
 602 
a This underestimates community onset infection, as evidenced by the much larger 603 
proportion of patients categorised as 'Accident and Emergency'. Patients presenting 604 
at Accident and Emergency with suspected bacteraemia and sepsis are likely to be 605 
admitted, with their isolates recorded as 'inpatient <48h'. 606 
Figures in the table are shown as percentages of available data. Overall 607 
completeness of each variable (for regions East Anglia / London / Northwest / 608 
Scotland / Wales / All) was: age 38/33/97/100/97/72%; sex 83/33/100/100/97/83%; 609 
source of isolate 38/33/90/100/65/62%; and origin 61/27/44/84/9/41%.   610 
 611 
Table 2. Faecal carriage of ESBL-E. coli in relation to patient demographics 612 
Overall isolation rates East Anglia London Northwest Scotland Wales Overall 




































       
No. isolates reviewed in detail and 
subjected to sequencing 
64 77 75 66 73 355 
Mean age, 
years; (SD)  
 56.9 (26.1) 33.4 (25.7) 48.3 (28.5) 60.3 (24.5) 64.2 (22.9) 52.1 (27.8) 
Sex (%) 
Female 32 (50.0) 41 (53.2) 38 (50.7) 42 (63.6) 42 (57.5) 195 (54.9) 
Male 32 (50.0) 36 (46.8) 36 (48.0) 24 (36.4) 31 (42.5) 159 (44.8) 
Missing data 0 (0.0) 0 (0.0) 1 (1.3) 0 (0.0) 0 ( 0.0) 1 (0.3) 
Overseas travel 
(%) 
Yes 6 (9.4) 32 (41.6) 13 (17.3) 6 (9.1) 42 (57.5) 99 (27.8) 
No 58 (90.6) 45 (58.4) 62 (82.7) 60 (90.9) 31 (42.5) 256 (72.1) 
Source of 
isolate (%) 
Community 44 (68.8) 54 (70.1) 42 (56.0) 23 (34.8) 36 (49.3) 199 (56.1) 
Inpatient (>48h) 9 (14.1) 20 (26.0) 20 (26.7) 32 (48.5) 26 (35.6) 107 (30.1) 
Inpatient (<48h) 9 (14.1) 3 ( 3.9) 7 ( 9.3) 11 (16.7) 11 (15.1) 41 (11.5) 





Yes 5 (7.8) 20 (26.0) 12 (16.0) 1 (1.5) 15 (20.5) 72 (20.3) 
No 13 (20.3) 43 (55.8) 0 (0.0) 2 (3.0) 14 (19.2) 53 (14.9) 
 Missing data 46 (71.9) 14 (18.2) 63 (84.0) 63 (95.5) 44 (60.3) 230 (64.8) 
Table 3.  Major STs among ESBL- E. coli found, by sample type 613 



















1 131 188 131 128 131 14 602 21 10 6 23 16a 
2 38 17 38 29 38 6 23 8 641 3 117 11b 
3 648  16 10 15 10 3 117 8   10 11c 
4 405 9 648 11   155 6   6284d 6e 
5 73 6 69 10   57 4   602 4f 
6 69 4 405 10   371 4   88 4g 
7 636 4 410 10   3776 4     




3 162 6   665 3     
10 10 3 443 6   2040 3     
No included in 
above major 
types 
 253  232  35  65  9  52 
Total isolates, 
all STs 
 293  360  65  111h  24  83i 
 614 
The top 10 STs are listed, except where a group has fewer than 3 representatives 615 
 616 
a 14/16 from chickens 617 
b 9/11 from cattle 618 
c 11/11 from cattle 619 
d Single locus variant of ST117: if these were grouped collectively, they would be the top ST from livestock 620 
e 6/6 from cattle 621 
f 4/4 from chicken 622 
g 2/4 from chicken; 2/4 from cattle 623 
h 106 chicken; 3 beef; 2 pork 624 
i 51 cattle; 29 chicken, 3 other. 625 
 626 
Table 4. ESBL types among major STs of E. coli from different sources 627 
 CTX-M ESBLs  
TEM: known or possible 
ESBLs 
 -15 -27 -14 -1 -24 -2 -3 -9 Other SHV -52 -117 -191 Other 
Bacteraemia 
131 159 24 5 - - - 2 - - - - - 4 - 
38 8 - 8 - - - - - - - - - - - 
648 16 - - - - - - - - - - - 1 - 
405 8 - 1 - - - - - - - - - - - 
73 4 - - 1 - - - 1 - - - - - - 
All 229 27 20 10 1 2 2 1 - 4 0 1 8 0 
Faeces 
131 98 18 7 1 - - - - 4a - - 1 - 2 
38 11 1 15 1 - - - - - 1 - - - 0 
10 8 - 1 3 - - - - 1 - - 1 - 1 
648 10 - 1 - - - - - - - - - - - 
69 6 - 2 - - - - - 1 - - - - - 
All 256 24 38 21 0 0 0 0 20 11 1 6 2 5 
Sewage 
131 13 1 - - - - - - - - - 1 - 3 
38 2 - 5 - - - - - - - - - - 5 
73 1 - - - - - - - - - - 1 - - 
648 2 - - - - - - - - - - - - 1 
10            2  1 
All 21 1 5 0 0 0 0 0 3 3 0 6 0 14 
Meat 
602 - - - 21 - - - - - - - - - - 
 628 
a Includes one isolate with Asn173Ser variant of CTX-M-27 629 
b Includes one isolate with novel Ser205Arg variant of CTX-M-1 630 
c All with CTX-M-214 631 
 632 
NB, some totals exceed numbers of isolates belonging to the ST as some isolates had >1 ESBL. The 633 
top 5 STs are included, except where they had <3 representatives  634 
23 - - - 8 - - - - - - - 1 - 4 
117 - - - 8 - - - - - - - - - - 
155 - - - 6 - - - - - - - - - - 
57 - - - 1 - - - - - 3 - - - - 
All 0 0 0 82 0 2 0 0 4 13 8 3 2 4 
Slurry 
10 1 - 2 1 - - - - - - - 1 - 0 
641 - - 1 2 - - - - - - - - - 1 
All 4 1 4 6 0 0 0 0 4b 0 0 2 0 1 
Animals 
23 1 - 1 12 - - - - - - - - - 9 
117 1 - 3 2 - - 3 0 2c - - 1 1 - 
10 3 - 7 - - 1 - - - - - 1 - - 
6284 - - 6 - - - - - - - - - - - 
602 - - 0 4 - - - - - - - - - - 
All 13 0 31 32 0 1 3 1 2 0 0 2 2 9 
Chicken    29          9 
Cattle 12 0 30 3 0 1 3 1 2 0 0 2 2 0 
 635 
 636 
Sunburst diagram (MS Excel) showing different E. coli strains and ESBL types 637 
predominating in specimen types from one-health compartments that relate to 638 
humans and animals. The inner circle presents the sources of ESBL-E. 639 
coli, segments are scaled according to the numbers of isolates found, single 640 
representatives of an ST are aggregated into the category ‘singletons’. The middle 641 
circle represents the numbers of isolates from each ST in relation to each ESBL and 642 
the outer circle represents the number of isolates with an ESBL-type. 643 
  644 
